3′-Deoxy-3′-18F-fluorothymidine PET-derived proliferative volume predicts overall survival in high-grade glioma patients

Journal of Nuclear Medicine

Volumn 53, Issue 12, 2012, Pages 1904-1910

  Idema, Albert J S ^a   Hoffmann, Aswin L ^a,b   Boogaarts, Hieronymus D ^a   Troost, Esther G C ^a,b   Wesseling, Pieter ^a,c   Heerschap, Arend ^a   Van Der Graaf, Winette T A ^a   Grotenhuis, J Andre ^a   Oyen, Wim J G ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

18F fluorothymidine; FLT; High grade glioma; Overall survival; PET CT

Indexed keywords

3' FLUOROTHYMIDINE F 18; TEMOZOLOMIDE; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; 3' FLUOROTHYMIDINE; DIAGNOSTIC AGENT;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BLOOD BRAIN BARRIER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST ENHANCEMENT; DRUG ACCUMULATION; EPENDYMOMA; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; MALE; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROLIFERATIVE VOLUME; QUANTITATIVE ANALYSIS; RADIATION DOSE; RADIOACTIVITY; RADIOLOGICAL PARAMETERS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SURVIVAL PREDICTION; SURVIVAL RATE; SURVIVAL TIME; TUMOR BIOPSY; TUMOR GROWTH; TUMOR VOLUME; BRAIN TUMOR; CELL PROLIFERATION; CLINICAL TRIAL; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SCINTISCANNING; TRANSPORT AT THE CELLULAR LEVEL;

ADULT; AGED; BIOLOGICAL TRANSPORT; BRAIN NEOPLASMS; CELL PROLIFERATION; DIDEOXYNUCLEOSIDES; FEMALE; GLIOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TUMOR BURDEN;

EID: 84870366816     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.105544     Document Type: Article

References (30)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996. (Pubitemid 40349501)
2. Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006;7:392-401.
3. Claes A, Idema AJ, Wesseling P. Diffuse glioma growth: a guerilla war. Acta Neuropathol. 2007;114:443-458. (Pubitemid 47521501)
4. Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol. 2008;26:1338-1345.
5. Ewelt C, Goeppert M, Rapp M, Steiger HJ, Stummer W, Sabel M. Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival. J Neurooncol. 2011;103:611-618.
6. Gorlia T, van den Bent MJ, Hegi ME, et al. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol. 2008;9:29-38.
7. 1H-magnetic resonance spectroscopy chemical shift imaging for detection of anaplastic foci in diffusely infiltrating gliomas with non-significant contrast-enhancement. J Neurol Neurosurg Psychiatry. 2011;82:512-520.
8. Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998;4:1334-1336. (Pubitemid 28512118)
9. Barwick T, Bencherif B, Mountz JM, Avril N. Molecular PET and PET/CT imaging of tumour cell proliferation using F-18 fluoro-L-thymidine: a comprehensive evaluation. Nucl Med Commun. 2009;30:908-917.
10. Kong XB, Zhu QY, Vidal PM, et al. Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3′-fluoro-3′-deoxythymidine and 3′-azido-3′-deoxythymidine. Antimicrob Agents Chemother. 1992;36:808-818.
11. 18F-FDG. J Nucl Med. 2005;46:945-952.
12. 18F-FLT human brain PET for the assessment of tumour proliferation in patients with high-grade glioma. Eur J Nucl Med Mol Imaging. 2009;36:1960-1967.
13. 18F]fluorothymidine positron-emission tomography: an image-guided biopsy study. Clin Radiol. 2009;64:52-63.
14. Ullrich R, Backes H, Li H, et al. Glioma proliferation as assessed by 3′-fluoro-3′-deoxy-L-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma. Clin Cancer Res. 2008;14:2049-2055. (Pubitemid 351551115)
15. 18F-fluorothymidine in patients with gliomas. J Nucl Med. 2006;47:1612-1621.
16. 18F]FLT). J Radioanal Nucl Chem. 2000;243:843-846.
17. 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients. J Nucl Med. 2007;48:726-735.
18. 18F-fluoro-deoxy-glucose- positron emission tomography-based target volume definition in head and neck cancer. Int J Radiat Oncol Biol Phys. 2007;69:1282-1289.
19. Daisne JF, SibomanaM, Bol A, Doumont T, Lonneux M, Gregoire V. Tri-dimensional automatic segmentation of PET volumes based on measured source-to-background ratios: influence of reconstruction algorithms. Radiother Oncol. 2003;69:247-250. (Pubitemid 37485998)
20. van Dalen JA, Hoffmann AL, Dicken V, et al. A novel iterative method for lesion delineation and volumetric quantification with FDG PET. Nucl Med Commun. 2007;28:485-493. (Pubitemid 46684199)
21. 18F]fluorothymidine (FLT) as a marker of proliferation in patients with recurrent gliomas: preliminary efficacy studies. Mol Imaging Biol. 2009;11:343-355.
22. 18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab. J Nucl Med. 2012;53:29-36.
23. 18F-fluorothymidine during treatment monitoring of recurrent high-grade glioma. J Nucl Med. 2010;51:720-727.
24. 18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol. 2007;25:4714-4721.
25. 18F-fluorothymidine PET tumor volume measurements. J Nucl Med. 2010;51:1368-1376.
26. Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR. 2003;24:1989-1998. (Pubitemid 37444849)
27. Law M, Oh S, Johnson G, et al. Perfusion magnetic resonance imaging predicts patient outcome as an adjunct to histopathology: a second reference standard in the surgical and nonsurgical treatment of low-grade gliomas. Neurosurgery. 2006;58:1099-1107. (Pubitemid 43879544)
28. Weber MA, Henze M, Tuttenberg J, et al. Biopsy targeting gliomas: do functional imaging techniques identify similar target areas? Invest Radiol. 2010;45:755-768.
29. 18F-fluorothymidine kinetic parameters to predict survival in patients with recurrent high-grade glioma. Clin Cancer Res. 2011;17:6553-6562.
30. Saga T, Kawashima H, Araki N, et al. Evaluation of primary brain tumors with FLT-PET: usefulness and limitations. Clin Nucl Med. 2006;31:774-780. (Pubitemid 44789556)